As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
HOME > COMMENTARY
COMMENTARY
-
JPWA’s Uniform Tax Representation Will Benefit Wholesalers and Customers Alike
November 10, 2014
-
Can a More-Open ICH Maintain “Tri-Polar” Leadership? - Key Focus at Lisbon Meeting
November 5, 2014
-
Ex-Health Minister Tamura’s Clout Likely to Grow in Nagatacho
October 14, 2014
-
MHLW Has Trick Up Its Sleeve to Skirt 3 Straight Years of “Full-Scale” NHI Price Revisions
October 6, 2014
-
Revised PAL to Embrace “Deeper” Safety Measures, Yet Also Escape Clauses to Ease Company Burdens
September 29, 2014
-
Series of CRPC Drugs Make Japan Debut, Expanded Indications Key to Success
September 24, 2014
-
Picture of Future Regulations on Investigator-Led Clinical Research Emerging
September 9, 2014
-
With No Pilot at Helm, Pharma Industry Embroiled in Confusion with Voluntary Funding Disclosures
September 1, 2014
-
Wholesalers’ Q1 Earnings Remain Positive, Medical Fee Cut Rule Seen to Boost Accuracy of Financial Results in Sept.
August 25, 2014
-
Japanese Drug Makers Working to Increase Pace of Drug Discovery by Optimizing Operations at Research Centers
August 18, 2014
-
PMDA Sets Target Review Times for Partial Changes to Generic Approval - A New Way to Underpin Stable Supply
August 4, 2014
-
Competition Fuels Personalized Medicine Market, First-Line Positions Eyed for Xalkori, Alecensa
July 28, 2014
-
Can New Fast-Track Review System Perk Up Drug Makers’ Development Drive in Japan?
July 7, 2014
-
June Reimbursement Listing Could Mark Watershed in Japan Generic Market
July 1, 2014
-
Two Reasons MHLW Opposes Yearly NHI Price Revisions, “Annual” Dropped from Gov’t Policy Guidelines
June 17, 2014
-
Delicate Balancing Act Required for SGLT-2 Inhibitor Promotions - Safety vs Efficacy
June 16, 2014
-
Why Not Make RMPs for Existing Products as Differentiation Strategy?
June 9, 2014
-
2013 Earnings Signal Foreign Drug Makers Losing Steam in Japan
June 2, 2014
-
Clinical Research Regulations at Crossroads: Guidelines or Legislation?
May 26, 2014
-
Was the Main Paper from VART Study “Practice” for a Grad Student?
May 19, 2014
ページ
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
An adult man who completed the administration of an investigational drug in a Japan PI study conducted by Eisai has died. Whether there was a causal relationship between the drug and the subject’s death remains unclear at the present time,…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Jascha Heifetz, widely regarded as one of the greatest violinists of all time, was once stopped, on 57th Street in Manhattan, by a pedestrian asking, “Could you tell me how to get to Carnegie Hall?” Heifetz pondered the question for…